James Hinrichs Appointed to Board of Directors and Chairman of the Audit Committee of Outset Medical

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Outset Medical CEO, Leslie Trigg said, “We are thrilled to have Jim join our Board of Directors. With a 30-year track record of both private and public company success, his governance and financial operations experience in high-growth environments will be invaluable to Outset.”

Mr. Hinrichs has held the role of Chief Financial Officer at multiple companies including Alere Inc. until its sale to Abbott Labs, and CareFusion Corporation until its sale to Becton Dickinson. Mr. Hinrichs also currently serves as a director of Orthofix Inc., Integer Holdings, Acutus Medical and Cibus. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.

“Outset is poised for significant growth, and I’m incredibly excited to join their board,” said Mr. Hinrichs. “The expanded commercialization of Tablo will give providers much-needed innovation to reduce the cost and complexity of delivering dialysis.”

Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.

Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated into a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.

spot_img

DON'T MISS

Related Articles